HTBX

Company Update (NASDAQ:HTBX): Heat Biologics Inc Resumes Enrollment in its Non-Small Cell Lung Cancer Trial Evaluating HS-110 in Combination with Anti-PD-1 Checkpoint Inhibitor

Heat Biologics Inc (NASDAQ:HTBX) announced that the company has resumed enrollment in its Phase 1b trial evaluating HS-110 in combination with nivolumab (Opdivo®), …

Corey Williams — September 14, 2016, 8:31 AM EDT

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts